Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
Open Access
- 27 February 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (5) , 1698-1707
Abstract
Purpose: Vorinostat [suberoylanilide hydroxamic acid (SAHA)] is a potent histone deacetylase inhibitor with promising clinical efficacy as an anticancer agent. In this preclinical study, we evaluated combining cytosine arabinoside [1-β-d-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Experimental design and interaction analysis of combination studies of drugs with log‐linear dose responsesStatistics in Medicine, 2008
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Contribution of Disruption of the Nuclear Factor-κB Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and FlavopiridolMolecular Pharmacology, 2004
- Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidJournal of Cellular Biochemistry, 2004
- Histone deacetylase inhibitors in cancer therapyCancer Cell, 2003
- Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measuresStatistics in Medicine, 2003
- Molecular sequelae of histone deacetylase inhibition in human malignant B cellsBlood, 2003
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Deacetylase Activity Associates with Topoisomerase II and Is Necessary for Etoposide-induced ApoptosisJournal of Biological Chemistry, 2001